Cholesterol Lowering Drug Safe and Effective in Children

Published Online: Wednesday, January 1, 2003
The cholesterol-lowering drug sim-vastatin significantly reduced cholesterol levels in children with inherited high cholesterol, according to a randomized study published in Circulation (October 1, 2002). A total of 173 children (aged 9 to 18 years) with inherited high cholesterol were randomized to up to 40 mg of simvastatin or placebo. After 48 weeks, the children who received simvastatin showed a 41% reduction in low-density lipoprotein, a 31% reduction in total cholesterol, a 34% reduction in apolipoprotein B, a 21% reduction in very low-density lipoprotein, and a 9% reduction in triglycerides. The drug did not affect the growth or maturation of the children.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues